Delta Air Lines Inc. (DAL), Summit Therapeutics PLC (ADR) (SMMT) & More: A Look at Five Stocks on the Move Today

Page 2 of 2

AstraZeneca PLC (ADR) (NYSE:AZN) stock is trading lower on the news of its Brilinta drug test failure. The company reported that the drug’s Phase 3 clinical trial failed to show a benefit over the older blood thinner clopidogrel for treating peripheral artery disease. The same drug had failed another test earlier this year in March as well. In other news, Aralez Pharmaceuticals inked an agreement with AstraZeneca via its subsidiary Aralez Pharmaceuticals Trading DAC, which involves commercial rights to generic Toprol-XL, which is a beta-blocker for the control of high blood pressure, chest pain and heart failure (see more details). A total of 24 funds from our database have positions in AstraZeneca with a total value of $542 million as of the end of June.

Follow Astrazeneca Plc (NYSE:AZN)

BP Plc (ADR) (NYSE:BP) is in the spotlight after it reported that its Clair offshore field is still closed following an oil leak on October 2. BP said that the field will remain closed until it finds conclusive reasons behind the leak. The leak lead to 95 metric tons of oil flowing into the sea. A total of 40 investors tracked by us amassed around $1.76 billion of BP stock at the end of June, compared to 34 funds holding stock worth $685 million in aggregate a quarter earlier.

Follow B P Plc (NYSE:BP)

Truett-Hurst Inc. (NASDAQ:THST)’s stock has plunged by over 8% amid news about the appointment of a new Chief Financial Officer. Earlier today, the company said Evan B. Meyer had been appointed as the new CFO, effective October 26. Meyer will replace Paul Forgue. Truett-Hurst Inc. (NASDAQ:THST) is a nano-cap company engaged in production and sale of wine and other wine-based alcohol beverages. Due to its small size, none of the funds tracked by us held shares at the end of June, although it’s important to mention that Jim Simons’ Renaissance Technologies and Ken Griffin’s Citadel Advisors both closed their positions during the second quarter.

Follow Truett-Hurst Inc. (NASDAQ:THST)

Disclosure: none

Page 2 of 2